Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives

Erlinda M Gordon, K Kumar Sankhala, Neal Chawla, Sant P Chawla, Erlinda M Gordon, K Kumar Sankhala, Neal Chawla, Sant P Chawla

Abstract

Trabectedin (ET743, Yondelis(®), manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian, Ecteinascidia turbinata, is a natural alkaloid with multiple complex mechanisms of action. On 23 October 2015, 15 years after the results of the first Phase 1 clinical trial using trabectedin for chemotherapy-resistant solid malignancies was reported, and 8 years after its approval in Europe, the United States Food and Drug Administration (USFDA) finally approved trabectedin for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma that has failed a prior anthracycline-containing regimen. Approval was based on the results of a pivotal Phase 3 trial involving a 2:1 randomization of 518 patients (who were further stratified by soft tissue sarcoma subtype), in which a significant improvement in progression-free survival was reported in the trabectedin-treated group vs. the dacarbazine-treated group (p < 0.001). In this trial, the most common adverse reactions were nausea, fatigue, vomiting, constipation, anorexia, diarrhea, peripheral edema, dyspnea, and headache, while the most serious were neutropenic sepsis, rhabdomyolysis, cardiomyopathy, hepatotoxicity, and extravasation leading to tissue necrosis. The most common grade 3-4 adverse events were laboratory abnormalities of myelosuppression in both arms and transient transaminitis in the trabectedin arm. In a recent Phase 2 trial, trabectedin had a similar outcome as doxorubicin when given as a single agent in the first-line setting. Studies are also being conducted to expand the use of trabectedin not only as a first-line cancer drug, but also for a number of other clinical indications, for example, in the case of mesenchymal chondrosarcoma, for which trabectedin has been reported to be exceptionally active. The possibility of combining trabectedin with targeted therapies, immune checkpoint inhibitors or virotherapy would also be an interesting concept. In short, trabectedin is an old new drug with proven potential to impact the lives of patients with soft tissue sarcoma and other solid malignancies.

Funding: Sarcoma Oncology Center, Santa Monica, CA 90405.

Keywords: Alkylating agent; Chemotherapy; Clinical trials; DNA minor groove binder; ET-743; Oncology; Soft tissue sarcoma; Trabectedin.

References

    1. American Cancer Society at . Accessed 28 Dec 2015.
    1. Petek BJ, Loggers ET, Pollack SM, Jones RI. Trabectedin in soft tissue sarcomas. Mar Drugs. 2015;13:974–983. doi: 10.3390/md13020974.
    1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–711. doi: 10.1056/NEJMra041866.
    1. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–1285.
    1. Jelic S, Kovcin V, Milanovic N, et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer. 1997;33:220–225. doi: 10.1016/S0959-8049(96)00297-3.
    1. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2676–2684.
    1. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003;3:CD003293.
    1. Van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic soft-tissue sarcoma (palette): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886. doi: 10.1016/S0140-6736(12)60651-5.
    1. D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9:2157–2163. doi: 10.1158/1535-7163.MCT-10-0263.
    1. Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the mre11-rad50-nbs1 complex. Mol Biol Cell. 2008;19:3969–3981. doi: 10.1091/mbc.E08-02-0215.
    1. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005;65:2964–2971. doi: 10.1158/0008-5472.CAN-04-4037.
    1. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235–2244. doi: 10.1158/0008-5472.CAN-09-2335.
    1. D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111:646–650. doi: 10.1038/bjc.2014.149.
    1. Reichardt P. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Futur Oncol. 2015;11(11 s):1. doi: 10.2217/fon.15.77.
    1. Van Kesteren C, Cvitkovic E, Taamma A, López-Lázaro L, Jimeno JM, Guzman C, Mathôt RAA, Schellens JHM, Misset JL, Brain E, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 2000;6:4725–4732.
    1. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients–preliminary evidence of activity. J Clin Oncol. 2001;19:1248–1255.
    1. Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez-Lazaro L, Rosing H, Jimeno JM, Cvitkovic E. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-h continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19:1256–1265.
    1. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-h continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7:231–242.
    1. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002;8:75–85.
    1. Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, et al. Phase I and pharmacokinetic study of Yondelis™ (ecteinascidin-743; et-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003;39:1842–1851. doi: 10.1016/S0959-8049(03)00458-1.
    1. Forouzesh B, Hidalgo M, Chu Q, Mita A, Mita M, Schwartz G, et al. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-h infusion weekly in patients with advanced solid malignancies. Clin Cancer Res. 2009;15:3591–3599. doi: 10.1158/1078-0432.CCR-08-2889.
    1. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin Cancer Res. 2008;14:6656–6662. doi: 10.1158/1078-0432.CCR-08-0336.
    1. Messersmith W, Jimeno A, Ettinger D, Lajeru D, Brahmer J, Lansery D, et al. Phase I trial of weekly trabectedin (et-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;63:181–188. doi: 10.1007/s00280-008-0733-7.
    1. Von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegulated liposomal doxorubicin in patients with advanced malignancies. Ann Onco. 2008;19:1802–1809. doi: 10.1093/annonc/mdn363.
    1. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, Braud FD, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45:2116–2122. doi: 10.1016/j.ejca.2009.04.002.
    1. Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2009;45:1153–1161. doi: 10.1016/j.ejca.2008.11.019.
    1. Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, YondelisR) in cancer patients. Clin Pharmacokinet. 2007;46:867–884. doi: 10.2165/00003088-200746100-00005.
    1. Ryan DP, Puchalski T, Supko JG, et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist. 2002;7:531–538. doi: 10.1634/theoncologist.7-6-531.
    1. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890–899. doi: 10.1200/JCO.2004.05.210.
    1. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–1490. doi: 10.1200/JCO.2004.02.098.
    1. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, et al. A phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2004;40:1327–1331. doi: 10.1016/j.ejca.2004.02.005.
    1. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase ii study of et-743 in advanced soft tissue sarcomas: a european organisation for the research and treatment of cancer (eortc) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576–584. doi: 10.1200/JCO.2005.01.180.
    1. Morgan JA, Le Cesne A, Chawla S, et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I) ASCO Meeting Abstracts. 2007;25:10060.
    1. Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol. 2012;124:48–52. doi: 10.1016/j.ygyno.2011.09.019.
    1. Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012;23:771–776. doi: 10.1093/annonc/mdr265.
    1. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase ii study of two different schedules. J Clin Oncol. 2009;27:4188–4196. doi: 10.1200/JCO.2008.21.0088.
    1. Huygh G, Clement PMJ, Dumez H, Schoffski P, Wildiers H, Selleslach J, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006; Article ID 56282:1–11.
    1. Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer. 2011;47:1006–1012. doi: 10.1016/j.ejca.2011.01.016.
    1. Grosso F, Jones RL, Demetri GD, Judson IR, Blay J-Y, Le Cesne A, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602. doi: 10.1016/S1470-2045(07)70175-4.
    1. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D’Incalci M, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011;123:553–556. doi: 10.1016/j.ygyno.2011.08.016.
    1. Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51:742–750. doi: 10.1016/j.ejca.2015.01.006.
    1. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50:1137–1147. doi: 10.1016/j.ejca.2014.01.012.
    1. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–793. doi: 10.1200/JCO.2015.62.4734.
    1. Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703–1709. doi: 10.1093/annonc/mds659.
    1. Prescribing information for Yondelis®. . Accessed 26 Apr 2016.
    1. Cassier PA, Dufresne A, Blay JV, Fayette J. Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Management. 2008;4:109–116.
    1. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42:1484–1490. doi: 10.1016/j.ejca.2006.02.010.
    1. European Medicines Agency. EMA/262441/2015; EMEA/H/C/000773.
    1. Syed I, Sudan M, Tseng WW, Arasheben S, Leong B, Aryanfar B, et al. Trabectedin: an active agent in the treatment of advanced mesenchymal chondrosarcoma. Salt Lake City: CTOS Annual Meeting; 2015.
    1. Kawai A, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomized, open-labe; phase 2 study. Lancet Oncol. 2015;16:406–416. doi: 10.1016/S1470-2045(15)70098-7.
    1. . Accessed 28 Dec 2015.
    1. Blay JV, Casali P, Nieto A, Tanovic A, Le Cesne A. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. Future Oncol. 2015;10:59–68. doi: 10.2217/fon.13.163.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit